Full text

Turn on search term navigation

Copyright © 2019 Sohab S. Radwan and Owen G. Schwartz. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. http://creativecommons.org/licenses/by/4.0/

Abstract

Regadenoson is a selective adenosine 2a (A2a) receptor agonist that is used in cardiac stress testing to evaluate for ischemic heart disease and has largely replaced adenosine in the modern era. Since adenosine receptors are involved in synaptic transmission between neurons throughout the central nervous system (CNS) including the cerebral cortex, hippocampus, and other structures as well, regadenoson can lower the seizure threshold in susceptible individuals. Epileptogenic activity is an uncommon yet potentially severe adverse effect of regadenoson use, and therefore, more awareness is required in screening patients at risk and evaluating alternate ways to investigate coronary artery disease (CAD) in susceptible individuals.

Details

Title
Seizure: An Adverse Effect of Regadenoson in Myocardial Perfusion Imaging
Author
Radwan, Sohab S  VIAFID ORCID Logo  ; Schwartz, Owen G
Editor
Assad Movahed
Publication year
2019
Publication date
2019
Publisher
John Wiley & Sons, Inc.
ISSN
20906404
e-ISSN
20906412
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2212651655
Copyright
Copyright © 2019 Sohab S. Radwan and Owen G. Schwartz. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. http://creativecommons.org/licenses/by/4.0/